<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Central hypothyroidism</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Central hypothyroidism</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Central hypothyroidism</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The overwhelming majority of patients who have hypothyroidism have thyroid disease (primary hypothyroidism). Central hypothyroidism refers to thyroid hormone deficiency due to a disorder of the pituitary, hypothalamus, or hypothalamic-pituitary portal circulation, resulting in diminished thyroid-stimulating hormone (TSH), thyrotropin-releasing hormone (TRH), or both. Pituitary TSH production is regulated in part by TRH, which is secreted from the paraventricular nucleus in the hypothalamus [<a href="#rid1">1</a>]. TRH is released into portal blood vessels and transported to the anterior pituitary gland where it regulates the synthesis, glycosylation, and release of TSH  (<a class="graphic graphic_figure graphicRef75399" href="/d/graphic/75399.html" rel="external">figure 1</a>). TSH stimulates the synthesis and secretion of triiodothyronine (T3) and thyroxine (T4). (See  <a class="medical medical_review" href="/d/html/7837.html" rel="external">"Thyroid hormone synthesis and physiology"</a>.)</p><p>The clinical features, diagnosis, and treatment of central hypothyroidism will be reviewed here. The approach to patients with primary, subclinical, and congenital hypothyroidism is reviewed separately. (See  <a class="medical medical_review" href="/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults"</a> and  <a class="medical medical_review" href="/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults"</a> and  <a class="medical medical_review" href="/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults"</a> and  <a class="medical medical_review" href="/d/html/5836.html" rel="external">"Clinical features and detection of congenital hypothyroidism"</a> and  <a class="medical medical_review" href="/d/html/5837.html" rel="external">"Treatment and prognosis of congenital hypothyroidism"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Central hypothyroidism is a rare cause of hypothyroidism, estimated to occur in 1:20,000 to 1:80,000 in the general population [<a href="#rid2">2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central hypothyroidism with coexisting pituitary hormone abnormalities</strong> – Patients with central hypothyroidism frequently have other pituitary hormone deficiencies. In this setting, the causes of central hypothyroidism are the same as the causes of hypopituitarism  (<a class="graphic graphic_table graphicRef55951" href="/d/graphic/55951.html" rel="external">table 1</a>) [<a href="#rid3">3,4</a>]. (See  <a class="medical medical_review" href="/d/html/6636.html" rel="external">"Causes of hypopituitarism"</a>.)</p><p></p><p class="bulletIndent1">Pituitary mass lesions, especially pituitary adenomas, are the most common cause of central hypothyroidism [<a href="#rid5">5</a>]. Pituitary tumors can cause central hypothyroidism by compressing pituitary thyrotrophs, which results in a decrease in TSH secretion; by interrupting the hypothalamic-pituitary portal blood flow, which results in disruption of the signaling between the hypothalamus and pituitary; or, rarely, by acute hemorrhage or infarction, resulting in pituitary apoplexy [<a href="#rid3">3,4</a>]. Other mass lesions that can cause central hypothyroidism include cysts and abscesses, meningiomas and dysgerminomas, metastatic tumors, and craniopharyngiomas, which may enter the sella or remain suprasellar.</p><p></p><p class="bulletIndent1">In addition, surgery or radiation therapy for pituitary adenomas or other mass lesions can cause central hypothyroidism. Radiation in high doses (≥30 to 40 Gray) to the brain, orbits, infratemporal, nasopharyngeal, or oropharyngeal regions can affect the pituitary gland or hypothalamus [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation", section on 'Endocrinopathies'</a>.)</p><p></p><p class="bulletIndent1">Other causes of central hypothyroidism with additional pituitary hormone abnormalities include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infiltrative disorders affecting the pituitary or hypothalamus (eg, hemochromatosis, lymphocytic hypophysitis, tuberculosis, syphilis, sarcoidosis, fungal infections, toxoplasmosis, and histiocytosis)</p><p class="bulletIndent2"><span class="glyph">•</span>Traumatic brain injury with injury to the pituitary stalk [<a href="#rid8">8</a>], stroke, subarachnoid hemorrhage </p><p class="bulletIndent2"><span class="glyph">•</span>Sheehan syndrome (postpartum pituitary necrosis).</p><p class="bulletIndent2"><span class="glyph">•</span>Developmental abnormalities, internal carotid aneurysms, and other central nervous system (CNS) tumors, which may cause hypothalamic damage</p><p class="bulletIndent2"><span class="glyph">•</span>Drug-induced endocrinopathies (eg, checkpoint inhibitor-induced hypophysitis) (see  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Hypophysitis'</a>)</p><p></p><p class="bulletIndent1">Growth hormone replacement therapy in growth hormone-deficient adults may unmask central hypothyroidism [<a href="#rid9">9,10</a>]. In one study of 84 patients with growth hormone deficiency, all of whom were initiating growth hormone therapy, 30 (36 percent) subsequently required <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> (T4) therapy because of reduced serum T4 concentrations [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolated central hypothyroidism</strong> – Idiopathic isolated TSH or thyrotropin-releasing hormone (TRH) deficiency is a rare cause of central hypothyroidism [<a href="#rid11">11,12</a>]. One cause of the former is treatment (of patients with lymphoma) with a retinoid X receptor ligand (<a class="drug drug_general" data-topicid="8695" href="/d/drug information/8695.html" rel="external">bexarotene</a>) that selectively inhibits TSH secretion [<a href="#rid13">13,14</a>].</p><p></p><p class="bulletIndent1">Isolated central hypothyroidism has also been described in patients taking psychotropic medication or antidepressants. In one study of 1022 patients with a low free T4 and low or normal TSH, 65 of 71 patients who appeared to have idiopathic central hypothyroidism were taking psychotropic or antidepressant medications [<a href="#rid15">15</a>]. The most common (taken by five or more patients) were <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>, <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a>, <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, and <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>. If this finding is confirmed, the diagnosis of isolated central hypothyroidism may become more common.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic causes</strong> – Several rare genetic defects have also been described [<a href="#rid16">16,17</a>]. These genetic mutations may cause isolated central hypothyroidism or combined pituitary hormone deficiencies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Central hypothyroidism may occur due to mutations in the TSH-beta subunit gene, the TRH receptor gene, in <em>TBL1X</em> (the gene encoding the subunit of the nuclear receptor co-repressor of the thyroid hormone receptor complex), in the <em>IGSF-1</em> gene (which also causes macroorchidism, by negative modulation of the TGFb1- and activin-Smad pathways), and in the <em>IRS4</em> (insulin receptor substrate 4) gene by an unknown mechanism [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Central hypothyroidism also occurs with combined pituitary hormone deficiencies due to mutations in multiple genes including pituitary transcription factors such as <em>POU1F1</em> (PIT1), <em>PROP1</em>, <em>HESX1</em>, <em>SOX3</em>, <em>SOX2</em>, and others. (See  <a class="medical medical_review" href="/d/html/6636.html" rel="external">"Causes of hypopituitarism", section on 'PIT-1'</a>.)</p><p></p><p class="headingAnchor" id="H18020064"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H18020398"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>The clinical manifestations of central hypothyroidism are similar to, but sometimes milder than, those of primary hypothyroidism. Common symptoms of central hypothyroidism include fatigue, cold intolerance, muscle cramps, headache, and weight gain  (<a class="graphic graphic_table graphicRef62676" href="/d/graphic/62676.html" rel="external">table 2</a>). Goiter is not a typical finding. (See  <a class="medical medical_review" href="/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism"</a>.)</p><p>Most patients with central hypothyroidism have a history of previous hypothalamic or pituitary disease, cranial irradiation, infiltrating disease, or trauma, with accompanying symptoms of deficiency or excess of other pituitary hormones [<a href="#rid2">2</a>]. In patients with coexisting pituitary hormone abnormalities, the symptoms of hypothyroidism may be less obvious. As an example, hot flashes due to hypogonadism may mask the cold intolerance of hypothyroidism. The coexistence of hypothyroidism and adrenal insufficiency may result in anorexia and weight loss, while hypothyroid, acromegalic patients may complain of sweating. Children may present with growth retardation and delayed sexual maturation, precocious puberty, or dwarfism and cretinism. The presence of polyuria and polydipsia suggests arginine vasopressin deficiency (previously called central diabetes insipidus) and posterior pituitary or hypothalamic involvement (eg, due to a craniopharyngioma).</p><p class="headingAnchor" id="H18020102"><span class="h2">Laboratory findings</span></p><p class="headingAnchor" id="H18020410"><span class="h3">Thyroid function tests</span><span class="headingEndMark"> — </span>In patients with central hypothyroidism, serum free T4 is low or low-normal, but serum TSH may be low, normal, or even slightly elevated (up to approximately 10 mU/L)  (<a class="graphic graphic_table graphicRef67935" href="/d/graphic/67935.html" rel="external">table 3</a>). In a retrospective study of 108 adult patients with central hypothyroidism (childhood onset, n = 26; adult onset, n = 82), initial free T4 results were in the low-normal range in only 18 percent of patients with adult onset (the remainder having levels below normal), compared with 65 percent of patients with childhood-onset central hypothyroidism [<a href="#rid19">19</a>]. In 51 patients, TSH was measured with a sensitive immunoradiometric assay, and the following results were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>8 percent of patients had low (&lt;0.2 mU/L) serum TSH concentrations</p><p class="bulletIndent1"><span class="glyph">●</span>84 percent had normal values</p><p class="bulletIndent1"><span class="glyph">●</span>8 percent had high (&gt;3.5 mU/L) values</p><p></p><p>Normal or high serum TSH concentrations in some patients with central hypothyroidism is due, in part, to the secretion of TSH that has reduced biologic activity but normal immunoactivity [<a href="#rid20">20,21</a>]. Reduced bioactivity is due to abnormalities in glycosylation of the TSH subunits, which is under the control of thyrotropin-releasing hormone (TRH) [<a href="#rid20">20,22</a>].</p><p>There is a diurnal rhythm in TSH secretion, with a surge late in the evening. This appears to be under hypothalamic control and is absent in many patients with central hypothyroidism [<a href="#rid23">23,24</a>]. Thus, TSH measurements may be normal during the daytime, but the absence of a nocturnal rise in TSH reduces the overall quantity of TSH secreted by the pituitary gland, causing clinical hypothyroidism.</p><p>In patients with central hypothyroidism, serum total and free T3 levels may be normal or low [<a href="#rid19">19,25</a>].</p><p class="headingAnchor" id="H18020236"><span class="h3">TRH stimulation test</span><span class="headingEndMark"> — </span>Although thyrotropin-releasing hormone (TRH) is not currently available in the United States, it is widely available in other countries. A TRH stimulation test involves the intravenous administration of TRH (200 mcg) with measurement of serum TSH at baseline and then 20 and 60 minutes after TRH administration. The normal increment in TSH at 20 minutes is 5 to 30 mU/L, with a subsequent decrease at 60 minutes [<a href="#rid26">26</a>]. Classically, one would expect no serum TSH response to TRH in patients with pituitary disease and a delayed response in patients with hypothalamic disease  (<a class="graphic graphic_figure graphicRef75399" href="/d/graphic/75399.html" rel="external">figure 1</a>). In fact, the response to TRH is highly variable in these circumstances, limiting the utility of this test in distinguishing between pituitary and hypothalamic disease as a cause of central hypothyroidism [<a href="#rid27">27</a>].</p><p>A TRH stimulation test may be useful in distinguishing nonthyroidal illness from central hypothyroidism due to pituitary disease. Patients with nonthyroidal illness have a blunted nocturnal rise in serum TSH concentrations, but they usually have a normal serum TSH response to TRH. (See <a class="local">'Transient central hypothyroidism'</a> below.)</p><p class="headingAnchor" id="H977219"><span class="h3">Other</span><span class="headingEndMark"> — </span>In patients with pituitary tumors, there may be laboratory evidence of deficiency or excess of other pituitary hormones, such as hypogonadism or hyperprolactinemia. (See  <a class="medical medical_review" href="/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses"</a>.)</p><p class="headingAnchor" id="H22447146"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of central hypothyroidism is based upon clinical manifestations and thyroid function tests. The majority of patients with central hypothyroidism have coexisting deficiencies in other pituitary hormones, although isolated TSH deficiency may also occur. Central hypothyroidism should be suspected in the following circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>There is known hypothalamic or pituitary disease</p><p class="bulletIndent1"><span class="glyph">●</span>A mass lesion is present in the pituitary</p><p class="bulletIndent1"><span class="glyph">●</span>When symptoms and signs of hypothyroidism are associated with other hormonal deficiencies</p><p></p><p>In hypothyroidism caused by hypothalamic or pituitary disease, TSH secretion does not increase appropriately as T4 secretion falls. Thus, we measure both serum TSH and free T4 if pituitary or hypothalamic disease is suspected. We also measure free T4 if the patient has convincing symptoms of hypothyroidism despite a normal TSH result.</p><p>In patients with central hypothyroidism, the serum free T4 value is low normal or low and serum TSH may be frankly low, inappropriately normal (for the low T4), or slightly high (5 to 10 mU/L) due to secretion of biologically inactive TSH  (<a class="graphic graphic_table graphicRef67935" href="/d/graphic/67935.html" rel="external">table 3</a>). In patients being monitored for central hypothyroidism (eg, irradiated childhood brain tumor survivors), a progressive decline in free T4 during surveillance is suggestive of central hypothyroidism [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults", section on 'Secondary and tertiary (central) hypothyroidism'</a>.)</p><p>It is not necessary to measure T3 in most patients with suspected central hypothyroidism. However, it may be helpful to measure T3 when the diagnosis of central hypothyroidism is uncertain. As an example, patients who are taking <a class="drug drug_general" data-topicid="9563" href="/d/drug information/9563.html" rel="external">liothyronine</a> (T3) supplements or who have autonomous thyroid nodules may have suppressed TSH and low free T4 levels, similar to that seen in patients with central hypothyroidism; however, serum T3 levels are usually elevated or high normal, rather than normal or low. (See <a class="local">'TSH low'</a> below.)</p><p class="headingAnchor" id="H10"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>For patients with a history of previous hypothalamic-pituitary disease, with accompanying symptoms of deficiency or excess of other pituitary hormones, and a low or low-normal free T4 with a low or inappropriately normal TSH, the diagnosis of central hypothyroidism is straightforward. However, for patients without previous hypothalamic/pituitary disease, it may be difficult to distinguish mild central hypothyroidism from mild primary hypothyroidism or subclinical hyperthyroidism. Some drugs can affect thyroid hormone metabolism, mimicking the thyroid function test abnormalities seen in patients with central hypothyroidism. In addition, transient central hypothyroidism may occur in some settings.</p><p class="headingAnchor" id="H11"><span class="h2">TSH slightly high</span></p><p class="bulletIndent1"><span class="glyph">●</span>Central versus primary hypothyroidism – A patient with a low serum total or free T4 concentration (eg, free T4 0.7 to 0.9 ng/dL [normal range 0.9 to 1.8 ng/dL]) and a slightly high serum TSH concentration (eg, 5 to 10 mU/L [normal range 0.5 to 5.0 mU/L]) could have either primary or central hypothyroidism. A higher serum TSH value would be expected if the patient had primary hypothyroidism, but since patients with central hypothyroidism may have elevations of biologically inactive TSH, definitive diagnosis requires further evaluation.</p><p></p><p class="bulletIndent1">In this setting, we measure anti-thyroid peroxidase (TPO) antibodies; follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol in premenopausal women with amenorrhea; FSH in postmenopausal women; and LH and testosterone in men. A high serum TPO antibody concentration suggests chronic autoimmune (Hashimoto's) thyroiditis and primary hypothyroidism, whereas absence of anti-TPO antibodies and abnormalities in other pituitary hormones favors central hypothyroidism. Amenorrhea in premenopausal women, the absence of high serum FSH concentrations in postmenopausal women, and low serum testosterone and normal or low LH concentrations in men suggest the presence of secondary hypogonadism. Hyperprolactinemia may be present in both central and primary hypothyroidism.</p><p></p><p class="headingAnchor" id="H12"><span class="h2">TSH low</span></p><p class="bulletIndent1"><span class="glyph">●</span>Central hypothyroidism versus subclinical hyperthyroidism – A patient with a low-normal serum total or free T4 value and a detectable but subnormal serum TSH concentration (eg, free T4 0.9 to 1.1 ng/dL, TSH 0.2 to 0.5 mU/L) could have either central hypothyroidism or subclinical hyperthyroidism.</p><p></p><p class="bulletIndent1">In this setting, serum T3 should be measured. Rarely, patients with subclinical hyperthyroidism who have low-normal free T4 values can have high-normal T3 values. The finding of a normal or high-normal serum T3 is consistent with subclinical hyperthyroidism. We then obtain a thyroid scan and uptake, looking for thyroid autonomy. If the scan shows areas of autonomy and the 24-hour uptake is normal or high-normal, autonomously functioning thyroid nodules or multinodular goiter are the most likely cause of subclinical hyperthyroidism.</p><p></p><p class="bulletIndent1">If the T3 is normal or low-normal, we evaluate for coexisting pituitary hormone abnormalities as described above.</p><p></p><p class="headingAnchor" id="H27846365"><span class="h2">TSH normal</span></p><p class="bulletIndent1"><span class="glyph">●</span>Central hypothyroidism versus euthyroid hypothyroxinemia – Many conditions result in increases or decreases in serum total T4 and T3 concentrations, but little change in serum free T4 and T3 concentrations and no symptoms or signs of thyroid dysfunction. Thus, in patients with a normal TSH and low total T4 concentrations, the serum free T4 should be measured. The detection of a normal serum TSH concentration associated with a low serum total T4 and normal free T4 concentration should alert the clinician to search for one of the causes of euthyroid hypothyroxinemia, especially if the patient has no symptoms or signs of hypothyroidism. (See  <a class="medical medical_review" href="/d/html/7892.html" rel="external">"Euthyroid hyperthyroxinemia and hypothyroxinemia", section on 'Euthyroid hypothyroxinemia due to binding protein abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug interaction – In patients with low serum total and free T4 concentrations (with a normal TSH concentration), central hypothyroidism is possible. However, certain drugs, especially antiseizure medications, such as <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> and <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, may be associated with an artifactually low serum free T4 and a normal serum TSH, mimicking central hypothyroidism [<a href="#rid29">29</a>]. In this case, assessment of other pituitary functions and pituitary imaging may be required to definitively rule out central hypothyroidism. In addition, thyrotropin-releasing hormone (TRH) testing, where available, can be very helpful in ruling out central hypothyroidism [<a href="#rid30">30</a>]. Patients with phenytoin-induced reductions in serum total and free T4 would have a normal TSH response to TRH administration, whereas patients with central hypothyroidism would have an absent or delayed response. <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">Mitotane</a>, a drug used to treat adrenocortical cancer, is also associated with a low free T4 and normal TSH, but unlike phenytoin, the TSH response to TRH is blunted. (See  <a class="medical medical_review" href="/d/html/7845.html" rel="external">"Drug interactions with thyroid hormones"</a>.)</p><p></p><p class="headingAnchor" id="H977108"><span class="h2">Transient central hypothyroidism</span><span class="headingEndMark"> — </span>There are three clinical situations in which the laboratory finding of central hypothyroidism is transient:</p><p class="bulletIndent1"><span class="glyph">●</span>After treatment of hyperthyroidism with an antithyroid drug, radioiodine, or surgery, serum TSH concentrations remain low for approximately 25 days. Serum free T4 values may fall to below normal during this period [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/7891.html" rel="external">"Laboratory assessment of thyroid function", section on 'Monitoring treatment of hyperthyroidism'</a> and  <a class="medical medical_review" href="/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment", section on 'Selection of therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum TSH concentrations may remain low for a similar period after T4 suppressive therapy is discontinued in a patient with a nodular goiter [<a href="#rid32">32</a>] or a history of thyroid cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with severe, nonthyroidal illness have transient central hypothyroidism. Thus, permanent central hypothyroidism should not be diagnosed in the presence of an underlying medical disease. (See  <a class="medical medical_review" href="/d/html/7817.html" rel="external">"Thyroid function in nonthyroidal illness"</a>.)</p><p></p><p>In these settings, clinical status and thyroid function tests (TSH, free T4) should be monitored serially (every four to six weeks) until thyroid tests return to normal. Additional evaluation is generally unnecessary.</p><p class="headingAnchor" id="H772203"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Patients with biochemical evidence of central hypothyroidism require neuroradiologic studies (preferably magnetic resonance imaging [MRI]) to assess the hypothalamic-pituitary region. If MRI is unavailable, a computed tomography (CT) scan with coronal views through the pituitary is a reasonable alternative.</p><p>Biochemical assessment of other pituitary hormone deficiencies, particularly secondary adrenal insufficiency, should be performed. Administration of <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> (T4) to patients with unsuspected and untreated secondary adrenal insufficiency can precipitate an acute adrenal crisis. Thus, pituitary-adrenal function should be assessed, usually by a corticotropin (ACTH) stimulation test, before T4 therapy is begun in all patients with central hypothyroidism. If adrenal insufficiency is present, glucocorticoid therapy should be given concomitantly with T4. (See  <a class="medical medical_review" href="/d/html/154.html" rel="external">"Determining the etiology of adrenal insufficiency in adults"</a>.)</p><p>Evaluation of other hypothalamic-pituitary hormonal function (gonadotropins, testosterone, estradiol, prolactin, insulin-like growth factor-1 [IGF-1]) to diagnose hormonal hypersecretion or hyposecretion is necessary in patients with a sellar mass on MRI. (See  <a class="medical medical_review" href="/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses", section on 'Evaluation of a sellar mass'</a>.)</p><p>In patients with normal findings on MRI, clinical and biochemical assessment of hypothalamic-pituitary hormonal function may be useful to differentiate central from mild primary hypothyroidism. (See <a class="local">'TSH slightly high'</a> above.)</p><p class="headingAnchor" id="H13"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Pituitary-adrenal function should be assessed, usually by a corticotropin (ACTH) stimulation test, before <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> therapy is begun in all patients with central hypothyroidism. If adrenal insufficiency is present, glucocorticoid therapy should be given concomitantly with T4. (See  <a class="medical medical_review" href="/d/html/154.html" rel="external">"Determining the etiology of adrenal insufficiency in adults"</a> and  <a class="medical medical_review" href="/d/html/6639.html" rel="external">"Diagnostic testing for hypopituitarism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The treatment of choice for correction of central hypothyroidism is synthetic <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a>. We suggest starting with a weight-based levothyroxine dose of 1.6 mcg/kg [<a href="#rid33">33</a>]. Another approach is to start with a lower dose and titrate to an endpoint slightly higher than the average normal free T4 value (ie, slightly higher than mid-normal); this approach is preferred in older patients or patients with underlying cardiovascular disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – The dose of <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> should be adjusted according to the patient's symptoms and serum free T4 values. The goal should be an average free T4 value for patients taking levothyroxine monotherapy. Since patients taking levothyroxine monotherapy have slightly higher serum T4 concentrations to compensate for the small deficit in T3, the free T4 should be slightly higher than mid-normal.</p><p></p><p class="bulletIndent1">Serum TSH cannot be used to monitor therapy, as it is suppressed to &lt;0.1 mU/L in nearly all patients taking doses of <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> that raise their serum free T4 concentrations to normal [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">In patients with pituitary tumors, central hypothyroidism may be reversible. Surgery may occasionally lead to an improvement in anterior pituitary function (see  <a class="medical medical_review" href="/d/html/6636.html" rel="external">"Causes of hypopituitarism", section on 'Mass lesions'</a>). Thyroid function (TSH, free T4) should be measured six to eight weeks after surgery. If a previously undetectable TSH becomes detectable, one can consider trying to taper the <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> dose while monitoring free T4 and TSH at four- to six-week intervals.</p><p></p><p>There is controversy regarding the goal for free T4 in patients with central hypothyroidism taking <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a>. In a randomized, crossover trial comparing thyroid hormone replacement regimens in patients with central hypothyroidism, higher dose T4 (1.6 mcg/kg) was superior to lower dose (1 mcg/kg) with respect to body mass index (BMI), lipid profile, and symptoms [<a href="#rid33">33</a>]. The resultant serum free T4 levels were at or slightly above the upper limit of normal. The widely accepted conclusion from this study is that the levothyroxine dose should be adjusted according to the patient's symptoms and serum free T4 values, aiming to maintain the serum free T4 concentration in the upper part of the normal range. However, it is well known that patients with primary hypothyroidism who take doses of levothyroxine that suppress TSH may have improved mental health and mood [<a href="#rid35">35</a>] and improved well-being [<a href="#rid36">36</a>] despite the cardiovascular and skeletal risks of iatrogenic subclinical hyperthyroidism (see  <a class="medical medical_review" href="/d/html/7881.html" rel="external">"Subclinical hyperthyroidism in nonpregnant adults"</a>). An analysis of a United Kingdom database of 525 patients with pituitary tumors found that 39 percent of those with central hypothyroidism taking levothyroxine had free T4 values less than 13 pmol/L (1.0 ng/dL; normal range 9 to 25 pmol/L [0.7 to 1.9 ng/dL]), compared with 13 percent of patients with primary hypothyroidism taking T4, suggesting the possibility that many patients with central hypothyroidism are undertreated [<a href="#rid37">37</a>].</p><p>The authors of another study suggest that patients with central hypothyroidism may need more <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> to achieve serum T4 values in the upper half of the normal range than patients with primary hypothyroidism caused by chronic autoimmune thyroiditis or radioiodine therapy. In this study of clinically euthyroid patients with serum free T4 index values in the upper half of the normal range, 36 patients with central hypothyroidism were receiving more levothyroxine (155 mcg/day, 1.9 mcg/kg/day) than 73 patients with hypothyroidism caused by chronic autoimmune thyroiditis or radioiodine therapy (118 mcg/day, 1.6 mcg/kg/day) [<a href="#rid38">38</a>]. It is unclear from this study whether aiming for a high normal free T4 in patients with central hypothyroidism results in excessive replacement therapy. In another study, women taking estrogen replacement therapy, men initiating growth hormone therapy, and patients with childhood-onset central hypothyroidism needed a higher dose of levothyroxine to maintain the free T4 in the upper half of the normal range [<a href="#rid19">19</a>].</p><p>There are insufficient data to determine whether combined <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> (T4) and T3 (in physiologic doses) is superior to levothyroxine monotherapy for patients with central hypothyroidism. Patients with central hypothyroidism may have low serum free T3 concentrations despite normal or upper normal free T4 values [<a href="#rid19">19,25</a>]. The potential benefit of combined T4-liothyronine (T3) treatment in 29 patients with central hypothyroidism was evaluated in a five-week, crossover trial comparing thyroid replacement regimens [<a href="#rid33">33</a>]. Although compared with T4 alone (1.6 mcg/kg), patients receiving combined T3 (0.16 mcg/kg) and T4 (1.44 mcg/kg) had a small but significant improvement in total cholesterol (198 versus 194 mg/dL) and normalization of ankle reflex time (380 versus 364 msec); the combined regimen resulted in supraphysiologic free T3 levels, suggesting hyperthyroidism. A full discussion of this topic can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Is there a role for combination T4 and T3 therapy?'</a>.)</p><p class="headingAnchor" id="H931854033"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109155.html" rel="external">"Society guideline links: Hypothyroidism"</a>.)</p><p class="headingAnchor" id="H1524904587"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – Central hypothyroidism refers to thyroid hormone deficiency due to a disorder of the pituitary, hypothalamus, or hypothalamic-pituitary portal circulation  (<a class="graphic graphic_figure graphicRef75399" href="/d/graphic/75399.html" rel="external">figure 1</a>). The prevalence of central hypothyroidism is much lower than that of primary hypothyroidism. Pituitary mass lesions, especially pituitary adenomas, are the most common cause of central hypothyroidism. Other mass lesions that can cause central hypothyroidism include cysts and abscesses, meningiomas and dysgerminomas, pituitary adenocarcinomas and metastatic tumors, and craniopharyngiomas, which may enter the sella or remain suprasellar  (<a class="graphic graphic_table graphicRef55951" href="/d/graphic/55951.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above and <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptoms</strong> – The clinical manifestations of central hypothyroidism are similar to, but sometimes milder than, those of primary hypothyroidism. Common symptoms of hypothyroidism include fatigue, cold intolerance, muscle cramps, and weight gain. The majority of patients with central hypothyroidism have coexisting deficiency or excesses of other pituitary hormones, although isolated thyroid-stimulating hormone (TSH) deficiency may also occur. In patients with coexisting pituitary hormone abnormalities, the symptoms of hypothyroidism may be masked by other symptoms of hypopituitarism. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory findings</strong> – In hypothyroidism caused by hypothalamic or pituitary disease, TSH secretion does not increase appropriately as thyroxine (T4) secretion falls. In patients with central hypothyroidism, serum free T4 is low or low normal, but serum TSH may be low, normal, or even slightly elevated (up to approximately 10 mU/L)  (<a class="graphic graphic_table graphicRef67935" href="/d/graphic/67935.html" rel="external">table 3</a>). In patients with pituitary tumors, there may be laboratory evidence of deficiency or excess of other pituitary hormones, such as hypogonadism or hyperprolactinemia. (See <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of central hypothyroidism is based upon clinical manifestations and thyroid function tests. We measure both serum TSH and free T4 if central hypothyroidism is suspected. We also measure free T4 if the patient has convincing symptoms of hypothyroidism despite a normal TSH result. In patients with central hypothyroidism, the serum free T4 value is low normal or low and serum TSH may be frankly low, inappropriately normal (for the low T4), or slightly high (5 to 10 mU/L) due to secretion of biologically inactive TSH  (<a class="graphic graphic_table graphicRef67935" href="/d/graphic/67935.html" rel="external">table 3</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – For patients without previous hypothalamic-pituitary disease, it may be difficult to distinguish mild central hypothyroidism from mild primary hypothyroidism or subclinical hyperthyroidism. Some drugs can affect thyroid hormone metabolism, mimicking the thyroid function test abnormalities seen in patients with central hypothyroidism. In addition, transient central hypothyroidism may occur in some settings. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Patients with biochemical evidence of central hypothyroidism require neuroradiologic studies (preferably magnetic resonance imaging [MRI]) to assess the hypothalamic-pituitary region and biochemical assessment of the other pituitary hormones, particularly secondary adrenal insufficiency. Administration of <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> to patients with unsuspected and untreated secondary adrenal insufficiency can precipitate an acute adrenal crisis. Thus, pituitary-adrenal function should be assessed, usually by a corticotropin (ACTH) stimulation test, before levothyroxine therapy is begun in all patients with central hypothyroidism, and glucocorticoid therapy should be given before or with levothyroxine if adrenal insufficiency is present. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– The treatment for correction of central hypothyroidism is synthetic <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a>. We typically start with a weight-based dose of 1.6 mcg/kg. Another approach is to start with a lower dose and titrate to a free T4 slightly higher than the average normal free T4 value. The dose should be adjusted according to the patient's symptoms and serum free T4 values, aiming for a free T4 value that is slightly higher than mid-normal. Serum TSH cannot be used to monitor therapy, as it is suppressed to &lt;0.1 mU/L in nearly all patients taking doses of levothyroxine that raise their serum free T4 concentrations to normal. (See <a class="local">'Treatment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kondo Y, Ozawa A, Kohno D, et al. The Hypothalamic Paraventricular Nucleus Is the Center of the Hypothalamic-Pituitary-Thyroid Axis for Regulating Thyroid Hormone Levels. Thyroid 2022; 32:105.</a></li><li><a class="nounderline abstract_t">Persani L. Clinical review: Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab 2012; 97:3068.</a></li><li><a class="nounderline abstract_t">Samuels MH, Ridgway EC. Central hypothyroidism. Endocrinol Metab Clin North Am 1992; 21:903.</a></li><li><a class="nounderline abstract_t">Yamada M, Mori M. Mechanisms related to the pathophysiology and management of central hypothyroidism. Nat Clin Pract Endocrinol Metab 2008; 4:683.</a></li><li><a class="nounderline abstract_t">Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996; 81:1169.</a></li><li><a class="nounderline abstract_t">Bhandare N, Kennedy L, Malyapa RS, et al. Primary and central hypothyroidism after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys 2007; 68:1131.</a></li><li class="breakAll">http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf (Accessed on November 18, 2019).</li><li><a class="nounderline abstract_t">Benvenga S, Vigo T, Ruggeri RM, et al. Severe head trauma in patients with unexplained central hypothyroidism. Am J Med 2004; 116:767.</a></li><li><a class="nounderline abstract_t">Agha A, Walker D, Perry L, et al. Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Clin Endocrinol (Oxf) 2007; 66:72.</a></li><li><a class="nounderline abstract_t">Porretti S, Giavoli C, Ronchi C, et al. Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory? J Clin Endocrinol Metab 2002; 87:2042.</a></li><li><a class="nounderline abstract_t">Gharib H, Abboud CF. Primary idiopathic hypothalamic hypothyroidism. Report of four cases. Am J Med 1987; 83:171.</a></li><li><a class="nounderline abstract_t">Yamakita N, Komaki T, Takao T, et al. Usefulness of thyrotropin (TSH)-releasing hormone test and nocturnal surge of TSH for diagnosis of isolated deficit of TSH secretion. J Clin Endocrinol Metab 2001; 86:1054.</a></li><li><a class="nounderline abstract_t">Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999; 340:1075.</a></li><li><a class="nounderline abstract_t">Toi N, Kurajoh M, Miyaoka D, et al. Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients. Endocr J 2022; 69:101.</a></li><li><a class="nounderline abstract_t">Keen F, Williams DM, Essame J, et al. Isolated central hypothyroidism: Underlying pathophysiology and relation to antidepressant and antipsychotic medications-A multi-centre South Wales study. Clin Endocrinol (Oxf) 2023.</a></li><li><a class="nounderline abstract_t">Tajima T, Nakamura A, Oguma M, Yamazaki M. Recent advances in research on isolated congenital central hypothyroidism. Clin Pediatr Endocrinol 2019; 28:69.</a></li><li><a class="nounderline abstract_t">Persani L, Brabant G, Dattani M, et al. 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism. Eur Thyroid J 2018; 7:225.</a></li><li><a class="nounderline abstract_t">Persani L, Bonomi M. The multiple genetic causes of central hypothyroidism. Best Pract Res Clin Endocrinol Metab 2017; 31:255.</a></li><li><a class="nounderline abstract_t">Alexopoulou O, Beguin C, De Nayer P, Maiter D. Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. Eur J Endocrinol 2004; 150:1.</a></li><li><a class="nounderline abstract_t">Beck-Peccoz P, Amr S, Menezes-Ferreira MM, et al. Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone. N Engl J Med 1985; 312:1085.</a></li><li><a class="nounderline abstract_t">Persani L, Ferretti E, Borgato S, et al. Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J Clin Endocrinol Metab 2000; 85:3631.</a></li><li><a class="nounderline abstract_t">Miura Y, Perkel VS, Papenberg KA, et al. Concanavalin-A, lentil, and ricin lectin affinity binding characteristics of human thyrotropin: differences in the sialylation of thyrotropin in sera of euthyroid, primary, and central hypothyroid patients. J Clin Endocrinol Metab 1989; 69:985.</a></li><li><a class="nounderline abstract_t">Samuels MH, Lillehei K, Kleinschmidt-Demasters BK, et al. Patterns of pulsatile pituitary glycoprotein secretion in central hypothyroidism and hypogonadism. J Clin Endocrinol Metab 1990; 70:391.</a></li><li><a class="nounderline abstract_t">Caron PJ, Nieman LK, Rose SR, Nisula BC. Deficient nocturnal surge of thyrotropin in central hypothyroidism. J Clin Endocrinol Metab 1986; 62:960.</a></li><li><a class="nounderline abstract_t">Ferretti E, Persani L, Jaffrain-Rea ML, et al. Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism. J Clin Endocrinol Metab 1999; 84:924.</a></li><li class="breakAll">http://www.pathology.leedsth.nhs.uk/dnn_bilm/Investigationprotocols/Pituitaryprotocols/TRHTest.aspx (Accessed on November 16, 2019).</li><li><a class="nounderline abstract_t">Hartoft-Nielsen ML, Lange M, Rasmussen AK, et al. Thyrotropin-releasing hormone stimulation test in patients with pituitary pathology. Horm Res 2004; 61:53.</a></li><li><a class="nounderline abstract_t">van Iersel L, Clement SC, Schouten-van Meeteren AYN, et al. Declining free thyroxine levels over time in irradiated childhood brain tumor survivors. Endocr Connect 2018; 7:1322.</a></li><li><a class="nounderline abstract_t">Surks MI, DeFesi CR. Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine. A paradox resolved. JAMA 1996; 275:1495.</a></li><li><a class="nounderline abstract_t">Connacher AA, Borsey DQ, Browning MC, et al. The effective evaluation of thyroid status in patients on phenytoin, carbamazepine or sodium valproate attending an epilepsy clinic. Postgrad Med J 1987; 63:841.</a></li><li><a class="nounderline abstract_t">Uy HL, Reasner CA, Samuels MH. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease. Am J Med 1995; 99:173.</a></li><li><a class="nounderline abstract_t">Vagenakis AG, Braverman LE, Azizi F, et al. Recovery of pituitary thyrotropic function after withdrawal of prolonged thyroid-suppression therapy. N Engl J Med 1975; 293:681.</a></li><li><a class="nounderline abstract_t">Slawik M, Klawitter B, Meiser E, et al. Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab 2007; 92:4115.</a></li><li><a class="nounderline abstract_t">Shimon I, Cohen O, Lubetsky A, Olchovsky D. Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism. Thyroid 2002; 12:823.</a></li><li><a class="nounderline abstract_t">Samuels MH, Schuff KG, Carlson NE, et al. Health status, mood, and cognition in experimentally induced subclinical thyrotoxicosis. J Clin Endocrinol Metab 2008; 93:1730.</a></li><li><a class="nounderline abstract_t">Carr D, McLeod DT, Parry G, Thornes HM. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol (Oxf) 1988; 28:325.</a></li><li><a class="nounderline abstract_t">Koulouri O, Auldin MA, Agarwal R, et al. Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine. Clin Endocrinol (Oxf) 2011; 74:744.</a></li><li><a class="nounderline abstract_t">Gordon MB, Gordon MS. Variations in adequate levothyroxine replacement therapy in patients with different causes of hypothyroidism. Endocr Pract 1999; 5:233.</a></li></ol></div><div id="topicVersionRevision">Topic 7849 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34726513" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The Hypothalamic Paraventricular Nucleus Is the Center of the Hypothalamic-Pituitary-Thyroid Axis for Regulating Thyroid Hormone Levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851492" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical review: Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1486881" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Central hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18941435" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mechanisms related to the pathophysiology and management of central hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8772595" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The effect of hypopituitarism on life expectancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17446000" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Primary and central hypothyroidism after radiotherapy for head-and-neck tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17446000" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Primary and central hypothyroidism after radiotherapy for head-and-neck tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15144914" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Severe head trauma in patients with unexplained central hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17201804" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11994338" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3111258" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Primary idiopathic hypothalamic hypothyroidism. Report of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11238485" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Usefulness of thyrotropin (TSH)-releasing hormone test and nocturnal surge of TSH for diagnosis of isolated deficit of TSH secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194237" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Central hypothyroidism associated with retinoid X receptor-selective ligands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34433736" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37749919" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Isolated central hypothyroidism: Underlying pathophysiology and relation to antidepressant and antipsychotic medications-A multi-centre South Wales study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31384098" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recent advances in research on isolated congenital central hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30374425" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28648512" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The multiple genetic causes of central hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14713273" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2984564" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11061514" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Circulating thyrotropin bioactivity in sporadic central hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2793998" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Concanavalin-A, lentil, and ricin lectin affinity binding characteristics of human thyrotropin: differences in the sialylation of thyrotropin in sera of euthyroid, primary, and central hypothyroid patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2105331" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Patterns of pulsatile pituitary glycoprotein secretion in central hypothyroidism and hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3958131" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Deficient nocturnal surge of thyrotropin in central hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084572" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084572" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14646390" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Thyrotropin-releasing hormone stimulation test in patients with pituitary pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30400062" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Declining free thyroxine levels over time in irradiated childhood brain tumor survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8622224" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine. A paradox resolved.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3128778" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The effective evaluation of thyroid status in patients on phenytoin, carbamazepine or sodium valproate attending an epilepsy clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7625422" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/808728" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Recovery of pituitary thyrotropic function after withdrawal of prolonged thyroid-suppression therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17711927" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12481949" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18285414" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Health status, mood, and cognition in experimentally induced subclinical thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3139338" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21521256" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15251659" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Variations in adequate levothyroxine replacement therapy in patients with different causes of hypothyroidism.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
